230 related articles for article (PubMed ID: 30553522)
21. Multivalent peptidic linker enables identification of preferred sites of conjugation for a potent thialanstatin antibody drug conjugate.
Puthenveetil S; He H; Loganzo F; Musto S; Teske J; Green M; Tan X; Hosselet C; Lucas J; Tumey LN; Sapra P; Subramanyam C; O'Donnell CJ; Graziani EI
PLoS One; 2017; 12(5):e0178452. PubMed ID: 28558059
[TBL] [Abstract][Full Text] [Related]
22. Development and Properties of Valine-Alanine based Antibody-Drug Conjugates with Monomethyl Auristatin E as the Potent Payload.
Wang Y; Fan S; Zhong W; Zhou X; Li S
Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28841157
[TBL] [Abstract][Full Text] [Related]
23. Site-selective modification strategies in antibody-drug conjugates.
Walsh SJ; Bargh JD; Dannheim FM; Hanby AR; Seki H; Counsell AJ; Ou X; Fowler E; Ashman N; Takada Y; Isidro-Llobet A; Parker JS; Carroll JS; Spring DR
Chem Soc Rev; 2021 Jan; 50(2):1305-1353. PubMed ID: 33290462
[TBL] [Abstract][Full Text] [Related]
24. Antibody-drug conjugates: an emerging modality for the treatment of cancer.
Leal M; Sapra P; Hurvitz SA; Senter P; Wahl A; Schutten M; Shah DK; Haddish-Berhane N; Kabbarah O
Ann N Y Acad Sci; 2014 Aug; 1321():41-54. PubMed ID: 25123209
[TBL] [Abstract][Full Text] [Related]
25. Antibody-drug conjugate payloads.
Anderl J; Faulstich H; Hechler T; Kulke M
Methods Mol Biol; 2013; 1045():51-70. PubMed ID: 23913141
[TBL] [Abstract][Full Text] [Related]
26. Physical and Chemical Stability of Antibody Drug Conjugates: Current Status.
Ross PL; Wolfe JL
J Pharm Sci; 2016 Feb; 105(2):391-397. PubMed ID: 26869406
[TBL] [Abstract][Full Text] [Related]
27. Development and evaluation of β-galactosidase-sensitive antibody-drug conjugates.
Kolodych S; Michel C; Delacroix S; Koniev O; Ehkirch A; Eberova J; Cianférani S; Renoux B; Krezel W; Poinot P; Muller CD; Papot S; Wagner A
Eur J Med Chem; 2017 Dec; 142():376-382. PubMed ID: 28818506
[TBL] [Abstract][Full Text] [Related]
28. The Chemical Design and Synthesis of Linkers Used in Antibody Drug Conjugates.
Frigerio M; Kyle AF
Curr Top Med Chem; 2017; 17(32):3393-3424. PubMed ID: 29357801
[TBL] [Abstract][Full Text] [Related]
29. Antibody-drug conjugates: a mini-review. The synopsis of two approved medicines.
Papachristos A; Pippa N; Demetzos C; Sivolapenko G
Drug Deliv; 2016 Jun; 23(5):1662-6. PubMed ID: 25625494
[TBL] [Abstract][Full Text] [Related]
30. Prospects and progress of antibody-drug conjugates in solid tumor therapies.
Govindan SV; Sharkey RM; Goldenberg DM
Expert Opin Biol Ther; 2016 Jul; 16(7):883-93. PubMed ID: 27045979
[TBL] [Abstract][Full Text] [Related]
31. Modulation of drug-linker design to enhance in vivo potency of homogeneous antibody-drug conjugates.
Pabst M; McDowell W; Manin A; Kyle A; Camper N; De Juan E; Parekh V; Rudge F; Makwana H; Kantner T; Parekh H; Michelet A; Sheng X; Popa G; Tucker C; Khayrzad F; Pollard D; Kozakowska K; Resende R; Jenkins A; Simoes F; Morris D; Williams P; Badescu G; Baker MP; Bird M; Frigerio M; Godwin A
J Control Release; 2017 May; 253():160-164. PubMed ID: 28257988
[TBL] [Abstract][Full Text] [Related]
32. Effects of Drug-Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody-Maytansinoid Conjugates.
Sun X; Ponte JF; Yoder NC; Laleau R; Coccia J; Lanieri L; Qiu Q; Wu R; Hong E; Bogalhas M; Wang L; Dong L; Setiady Y; Maloney EK; Ab O; Zhang X; Pinkas J; Keating TA; Chari R; Erickson HK; Lambert JM
Bioconjug Chem; 2017 May; 28(5):1371-1381. PubMed ID: 28388844
[TBL] [Abstract][Full Text] [Related]
33. Design, Synthesis, and in vitro Evaluation of Multivalent Drug Linkers for High-Drug-Load Antibody-Drug Conjugates.
Chen B; Gianolio DA; Stefano JE; Manning CM; Gregory RC; Busch MM; Brondyk WH; Miller RJ; Dhal PK
ChemMedChem; 2018 Apr; 13(8):790-794. PubMed ID: 29517131
[TBL] [Abstract][Full Text] [Related]
34. Sortase Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody Drug Conjugates with High In Vitro and In Vivo Potency.
Beerli RR; Hell T; Merkel AS; Grawunder U
PLoS One; 2015; 10(7):e0131177. PubMed ID: 26132162
[TBL] [Abstract][Full Text] [Related]
35. Current methods for the synthesis of homogeneous antibody-drug conjugates.
Sochaj AM; Świderska KW; Otlewski J
Biotechnol Adv; 2015 Nov; 33(6 Pt 1):775-84. PubMed ID: 25981886
[TBL] [Abstract][Full Text] [Related]
36. The next generation of antibody drug conjugates.
Mack F; Ritchie M; Sapra P
Semin Oncol; 2014 Oct; 41(5):637-52. PubMed ID: 25440608
[TBL] [Abstract][Full Text] [Related]
37. [Design of next generation antibody drug conjugates].
Zhu GD; Fu YX
Yao Xue Xue Bao; 2013 Jul; 48(7):1053-70. PubMed ID: 24133971
[TBL] [Abstract][Full Text] [Related]
38. Natural Product Splicing Inhibitors: A New Class of Antibody-Drug Conjugate (ADC) Payloads.
Puthenveetil S; Loganzo F; He H; Dirico K; Green M; Teske J; Musto S; Clark T; Rago B; Koehn F; Veneziale R; Falahaptisheh H; Han X; Barletta F; Lucas J; Subramanyam C; O'Donnell CJ; Tumey LN; Sapra P; Gerber HP; Ma D; Graziani EI
Bioconjug Chem; 2016 Aug; 27(8):1880-8. PubMed ID: 27412791
[TBL] [Abstract][Full Text] [Related]
39. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
40. Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads.
Masters JC; Nickens DJ; Xuan D; Shazer RL; Amantea M
Invest New Drugs; 2018 Feb; 36(1):121-135. PubMed ID: 29027591
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
